Sirolimus in COVID-19 Phase 1

Summary

This is a double-blinded, two-arm, randomized, placebo controlled study comparing the virological efficacy of add-on sirolimus with standard care to placebo and standard care. Virological efficacy is defined as the change from baseline to day 7 in SARS-CoV-2 viral burden measured by quantitative real-time polymerase chain reaction.

Timeline

Start

2020-07-06

Primary completion

2021-07-30

Completion

2021-07-30

Drugs

Indications